CDK4
Cyclin-dependent kinase 4
As of the edition of 20 October 2026, CDK4 (cyclin-dependent kinase 4, UniProt P11802) has 22 drugs tested at it and 26 companies on the list, 10 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P11802
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 15
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Urinary and reproductive; Immune system; Digestive system; Pregnancy and women's health; Hormones
- Registered trials of its drugs
- 865
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 2 |
| Stopped | 11 |
| Status not established | 3 |
| Total | 22 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Palbociclib | Marketed | Phase 4 | Ends 2034 |
| Abemaciclib | Marketed | Phase 4 | Ends 2031 |
| Ribociclib | Marketed | Phase 4 | Ends 2031 |
| Alvocidib | Stopped | Phase 2 | none listed |
| Trilaciclib | Marketed | Phase 4 | Ends 2040 |
| UCN-01 | Stopped | Phase 2 | none listed |
| Atirmociclib | Active | Phase 3 | none listed |
| Riviciclib | Went quiet | Phase 2 | none listed |
| Culmerciclib | Status not established | Phase 2 | none listed |
| SPH4336 | Active | Phase 3 | none listed |
| Lerociclib | Stopped | Phase 3 | none listed |
| Milciclib | Stopped | Phase 2 | none listed |
12 of 22 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 10 |
| Route B | 4 |
| Engaged | 9 |
| Undetermined | 3 |
| Total on the list | 26 |
The other 23 companies at CDK4
In the product26 companies in all; 23 are not named here, and no score is.
See the 26 companies at CDK4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.